9.64
3.26%
-0.33
전일 마감가:
$9.97
열려 있는:
$9.92
하루 거래량:
204.74K
Relative Volume:
1.08
시가총액:
$475.15M
수익:
$62.02M
순이익/손실:
$-45.65M
주가수익비율:
0.8486
EPS:
11.36
순현금흐름:
$-9.60M
1주 성능:
+0.78%
1개월 성능:
+11.37%
6개월 성능:
+5.76%
1년 성능:
-6.18%
Theravance Biopharma Inc Stock (TBPH) Company Profile
명칭
Theravance Biopharma Inc
전화
650-808-6000
주소
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
TBPH을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
TBPH | 9.64 | 475.15M | 62.02M | -45.65M | -9.60M | 11.36 |
VRTX | 449.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 746.04 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 595.85 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 247.02 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 108.14 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2022-05-23 | 개시 | SVB Leerink | Outperform |
2021-11-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
2021-09-15 | 다운그레이드 | JP Morgan | Overweight → Underweight |
2021-08-25 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
2021-08-24 | 다운그레이드 | Cowen | Outperform → Market Perform |
2020-10-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2020-07-07 | 개시 | JP Morgan | Overweight |
2020-06-15 | 개시 | Morgan Stanley | Equal-Weight |
2020-05-13 | 개시 | Cowen | Outperform |
2020-01-08 | 재확인 | H.C. Wainwright | Buy |
2019-11-06 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
2019-10-29 | 개시 | H.C. Wainwright | Buy |
2018-03-29 | 재개 | Piper Jaffray | Overweight |
2017-08-17 | 개시 | Evercore ISI | Outperform |
2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
2017-05-11 | 재확인 | Needham | Buy |
2016-12-21 | 개시 | Needham | Buy |
2016-11-03 | 개시 | Piper Jaffray | Overweight |
2016-10-12 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
2016-08-03 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
2016-06-20 | 개시 | Guggenheim | Buy |
2016-06-20 | 재확인 | Leerink Partners | Outperform |
2016-05-12 | 개시 | Leerink Partners | Outperform |
2016-05-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
2015-02-03 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
모두보기
Theravance Biopharma Inc 주식(TBPH)의 최신 뉴스
Multiple System Atrophy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma - The Globe and Mail
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
Theravance Biopharma to Present at Evercore HealthCONx Conference | TBPH Stock News - StockTitan
Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates - MSN
(TBPH) Investment Report - Stock Traders Daily
Theravance Biopharma Inc (TBPH) Quarterly 10-Q Report - Quartzy
Madison Avenue Partners, LP Expands Stake in Theravance Biopharm - GuruFocus.com
Theravance Biopharma Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - MarketBeat
Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares - Investing.com India
Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares By Investing.com - Investing.com Canada
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2024 Earnings Call Transcript - Insider Monkey
Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Initiatives - GuruFocus.com
Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Theravance Biopharma’s Third Quarter 2024 Financial Insights - TipRanks
Theravance Biopharma Q3 2024 Earnings: Revenue Surpasses Estimat - GuruFocus.com
Theravance Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
With Theravance Biopharma, Inc. (NASDAQ:TBPH) It Looks Like You'll Get What You Pay For - Simply Wall St
Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value - PR Newswire
What To Expect From Theravance Biopharma Inc (TBPH) Q3 2024 Earnings - GuruFocus.com
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance - Yahoo Finance
Theravance Biopharma (TBPH) Scheduled to Post Earnings on Tuesday - Defense World
5 Small Drug Stocks to Buy as Trump Gets Re-Elected - Yahoo Finance
Theravance Biopharma (TBPH) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Theravance Biophar - GuruFocus.com
(TBPH) Proactive Strategies - Stock Traders Daily
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by SG Americas Securities LLC - MarketBeat
When (TBPH) Moves Investors should Listen - Stock Traders Daily
Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024 - StockTitan
Q3 EPS Estimate for Theravance Biopharma Boosted by Analyst - MarketBeat
Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - Defense World
What is Zacks Research's Estimate for TBPH Q4 Earnings? - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Rating of "Hold" by Analysts - MarketBeat
The Manufacturers Life Insurance Company Decreases Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance study shows YUPELRI improves COPD lung function By Investing.com - Investing.com Australia
Theravance Biopharma (NASDAQ:TBPH) Shares Pass Below 200 Day Moving AverageHere's What Happened - MarketBeat
Theravance study shows YUPELRI improves COPD lung function - Investing.com
Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease - StockTitan
Where are the Opportunities in (TBPH) - Stock Traders Daily
Dimensional Fund Advisors LP Has $2.80 Million Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma (STU:0TB) Price-to-Operating-Cash-Flow : (As of Oct. 10, 2024) - GuruFocus.com
Squarepoint Ops LLC Takes $986,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Bank of Montreal Can Raises Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock Holdings Lifted by Marshall Wace LLP - MarketBeat
(TBPH) Pivots Trading Plans and Risk Controls - Stock Traders Daily
XTX Topco Ltd Purchases New Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y - MSN
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Rhumbline Advisers Sells 15,095 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma Inc (TBPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Theravance Biopharma Inc 주식 (TBPH) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Samaha Eli | 10% Owner |
Aug 07 '24 |
Buy |
7.80 |
999,800 |
7,798,440 |
9,511,150 |
Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS |
Jul 10 '24 |
Sale |
9.00 |
4,000 |
36,000 |
335,965 |
Samaha Eli | 10% Owner |
May 01 '24 |
Buy |
8.75 |
1,499,124 |
13,117,335 |
8,511,350 |
Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS |
Feb 22 '24 |
Sale |
8.71 |
1,254 |
10,922 |
311,733 |
자본화:
|
볼륨(24시간):